'Designer drugs': Update on the management of novel psychoactive substance misuse in the acute care setting

Clinical Medicine, Journal of the Royal College of Physicians of London

Volumn 14, Issue 4, 2014, Pages 409-415

  Smith, Christopher D ^a   Robert, Stefanie ^b  

^a WHIPPS CROSS UNIVERSITY HOSPITAL   (United Kingdom)

^b HOMERTON UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Complications; Designer drugs; Legal highs; Management; Novel psychoactive substances

Indexed keywords

4 HYDROXYBUTYRIC ACID; ANESTHETIC AGENT; BENZODIAZEPINE; CANNABINOID RECEPTOR AGONIST; CATHINONE; DESIGNER DRUG; GAMMA BUTYROLACTONE; METHOXETAMINE; MUSCLE RELAXANT AGENT; PIPERAZINE DERIVATIVE; SEROTONIN 2A ANTAGONIST; SEROTONIN ANTAGONIST; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ADULT; AGITATION; ANXIETY; ARTICLE; ARTIFICIAL VENTILATION; CASE REPORT; CATATONIA; CONFUSION; COOLING; DELIRIUM; DIZZINESS; DRUG MISUSE; EMERGENCY CARE; ENDOTRACHEAL INTUBATION; EUPHORIA; GLASGOW COMA SCALE; HUMAN; HYPERPYREXIA; HYPERTENSION; HYPERTHERMIA; HYPONATREMIA; MALE; METABOLIC ACIDOSIS; MULTIPLE ORGAN FAILURE; MUSCLE HYPERTONIA; PARALYSIS; PARANOIA; PSYCHOSIS; RHABDOMYOLYSIS; SEIZURE; SEROTONIN SYNDROME; SOMNOLENCE; TACHYCARDIA; TREMOR; WITHDRAWAL SYNDROME;

COMPLICATIONS; DESIGNER DRUGS; LEGAL HIGHS; MANAGEMENT; NOVEL PSYCHOACTIVE SUBSTANCES;

ALKALOIDS; CANNABINOID RECEPTOR AGONISTS; DESIGNER DRUGS; HUMANS; PIPERAZINES; PSYCHOTROPIC DRUGS; SODIUM OXYBATE; SUBSTANCE-RELATED DISORDERS;

EID: 84906082887     PISSN: 14702118     EISSN: 14734893     Source Type: Journal    
DOI: 10.7861/clinmedicine.14-4-409     Document Type: Article

References (47)

1. Smith CD, Williams M, Shaikh M. Novel psychoactive substances: a novel clinical challenge. BMJ Case Rep 2013; 1-3.
2. Home Office. Drug misuse: findings from the 2012/13 Crime Survey for England and Wales. London: Home Office, 2013. www.gov.uk/government/ publications/drug-misuse-findings-from-the-2012-to-2013-csew [Accessed 6 June 2014].
3. European Monitoring Centre for Drugs and Drug Addiction. European drug report 2013: trends and developments. Lisbon: EMCDDA, 2013. www.emcdda.europa. eu/publications/edr/trends-developments/2013 [Accessed 6 June 2014].
4. Maxwell JC. Psychoactive substances - Some new, some old: A scan of the situation in the US. Drug Alcohol Depend 134;71-7.
5. Schmidt MM, Sharma A, Schifano F, Feinmann C. 'Legal highs' on the net - Evaluation of UK-based Websites, products and product information. Forensic Sci Int 2011;206:92-7.
6. Lancet. Legal highs and lows-illicit drug use around the world. Lancet 2013;382:1.
7. McElrath K, Van Hout MC. A preference for mephedrone: Drug markets, drugs of choice, and the emerging 'legal high' scene. J Drug Issues 2011;41:487-508.
8. Office for National Statistics. Deaths Related to Drug Poisoning in England and Wales, 2011. www.ons.gov.uk/ons/publications/re-reference-tables. html?edition=tcm%3A77-266060 [Accessed 15 July 2014].
9. Spiller HA, Ryan ML, Weston RG, Jansen J. Clinical experience with and analytical confirmation of 'bath salts' and 'legal highs' (synthetic cathinones) in the United States. Clin Toxicol (Phila) 2011;49:499-505.
10. Lank PM, Pines E, Mycyk MB. Emergency physicians' knowledge of cannabinoid designer drugs. West J Emerg Med 2013;14:467-70.
11. Prosser JM, Nelson LS. The toxicology of bath salts: a review of synthetic cathinones. J Med Toxicol 2012;8:33-42.
12. Advisory Council on the Misuse of Drugs. Consideration of the novel psychoactive substances ('legal highs'). London: ACMD, 2011. www.gov.uk/government/uploads/system/uploads/attachment-data/file/119139/ acmdnps2011.pdf [Accessed 6 June 2014].
13. European Monitoring Centre for Drugs and Drug Addiction. Synthetic cathinones, 2012. www.emcdda.europa.eu/publications/drug-profiles/synthetic- cathinones [Accessed 6 June 2014].
14. Wood DM, Dargan PI. Understanding how data triangulation identifies acute toxicity of novel psychoactive drugs. J Med Toxicol 2012;8:300-3.
15. Wood DM, Greene SL, Dargan PI. Clinical pattern of toxicity associated with the novel synthetic cathinone mephedrone. Emerg Med J 2011;28:280-2.
16. Thornton SL, Gerona RR, Tomaszewski C. Psychosis from a bath salt product containing flephedrone and MDPV with serum, urine, and product quantification. J Med Toxicol 2012;8:310-3.
17. Schifano F, Albanese A, Fergus S. Mephedrone (4-methylmethcathinone; 'meow meow'): chemical, pharmacological and clinical issues. Psychopharmacology (Berl) 2011;214:593-602.
18. Wikström M, Thelander G, Nyström I, Kronstrand R. Two Fatal Intoxications with the New Designer Drug Methedrone (4-Methoxymethcathinone). Autopsy cases 2010;34:594-8.
19. Buckley NA, Dawson AH, Isbister GK. Serotonin syndrome. BMJ 2014;348:g1626.
20. Murray BL, Murphy CM, Beuhler MC. Death following recreational use of designer drug 'bath salts' containing 3,4-methylenedioxypy-rovalerone (MDPV). J Med Toxicol 2012;8:69-75.
21. Coppola M, Mondola R. Synthetic cathinones: chemistry, pharmacology and toxicology of a new class of designer drugs of abuse marketed as 'bath salts' or 'plant food'. Toxicol Lett 2012;211:144-9.
22. Rusyniak DE, Tandy SL, Hekmatyar SK. The role of mitochondrial uncoupling in 3, 4-methylenedioxymethamphetamine-mediated skeletal muscle hyperthermia and rhabdomyolysis. J Pharmacol Exp Ther 2005;313:629-39. (Pubitemid 40604163)
23. Boyer EW, Shannon M. The Serotonin Syndrome. N Engl J Med 2005;352:1112-20.
24. Vaidya C, Ho W, Freda BJ. Management of hyponatremia: providing treatment and avoiding harm. Cleve Clin J Med 2010;77:715-26.
25. Kalantar-Zadeh K, Nguyen MK, Chang R, Kurtz I. Fatal hyponatremia in a young woman after ecstasy ingestion. Nat Clin Pract Nephrol 2006;2:283-8. (Pubitemid 43787261)
26. Bajaj N, Mullen D, Wylie S. Dependence and psychosis with 4-methylmethcathinone (mephedrone) use. BMJ Case Rep 2010; doi: 10.1136/bcr.02.2010.2780.
27. Cohen BM, Butler R. BZP-party pills: a review of research on benzylpiperazine as a recreational drug. Int J Drug Policy 2011;22:95-101.
28. Arbo MD, Bastos ML, Carmo HF. Piperazine compounds as drugs of abuse. Drug Alcohol Depend 2012;122:174-85.
29. European Monitoring Centre for Drugs and Drug Addiction. BZP and other piperazines, 2011. www.emcdda.europa.eu/publications/drug-profiles/bzp [Accessed 6 June 2014].
30. Gee P, Richardson S, Woltersdorf W, Moore G. Toxic effects of BZP-based herbal party pills in humans: a prospective study in Christchurch, New Zealand. N Z Med J 2005;118:U1784.
31. Gee P, Gilbert M, Richardson S. Toxicity from the recreational use of 1-benzylpiperazine. Clin Toxicol (Phila) 2008;46:802-7.
32. Austin H, Monasterio E. Acute psychosis following ingestion of 'Rapture'. Australas Psychiatry 2004;12:406-8. (Pubitemid 40103734)
33. World Health Organization. Gamma-butyrolactone (GBL): pre-review report. Geneva: WHO, 2014. www.who.int/medicines/areas/quality-safety/4-3-Review.pdf [Accessed 6 June 2014].
34. Bell J, Collins R. Gamma-butyrolactone (GBL) dependence and withdrawal. Addiction 2011;106:442-7.
35. Measham F, Wood DM, Dargan PI, Moore K. The rise in legal highs: prevalence and patterns in the use of illegal drugs and first- and second-generation 'legal highs' in South London gay dance clubs. J Subst Use 2011;16:263-72.
36. McDaniel CH, Miotto KA. Gamma hydroxybutyrate (GHB) and gamma butyrolactone (GBL) withdrawal: five case studies. J Psychoactive Drugs 2001;33:143-9. (Pubitemid 32643296)
37. Kashyap GL, Patel AG. Unusual presentation of a patient with GBL withdrawal: a case report. Psychiatr Danub 2011;23:S32-4.
38. Advisory Council on the Misuse of Drugs. Methoxetamine report. London: ACMD, 2012. www.gov.uk/government/publications/advisory-council-on-the-misuse- of-drugs-acmd-methoxetamine-report-2012 [Accessed 6 June 2014].
39. Corazza O, Schifano F, Simonato P. Phenomenon of new drugs on the Internet: the case of ketamine derivative methoxetamine. Hum Psychopharmacol 2012;27:145-9.
40. Advisory Council on the Misuse of Drugs. Consideration of the major cannabinoid agonists. London: ADMD, 2009. www.gov.uk/government/uploads/system/ uploads/attachment-data/file/119149/acmd-report-agonists.pdf [Accessed 6 June 2014].
41. European Monitoring Centre for Drugs and Drug Addiction. Drug profile: Synthetic cannabinoids and 'Spice', 2011. www.emcdda.europa.eu/publications/ drug-profiles/synthetic-cannabinoids [Accessed 6 June 2014].
42. Spaderna M, Addy PH, D'Souza DC. Spicing things up: synthetic cannabinoids. Psychopharmacology (Berl) 2013;228:525-40.
43. Mir A, Obafemi A, Young A, Kane C. Myocardial infarction associated with use of the synthetic cannabinoid K2. Pediatrics 2011;128:e1622-7.
44. Bhanushali GK, Jain G, Fatima H et al. AKI associated with synthetic cannabinoids: a case series. Clin J Am Soc Nephrol 2013;8:523-6.
45. Durand D, Delgado LL, de la Parra-Pellot DM, Nichols-Vinueza D. Psychosis and severe rhabdomyolysis associated with synthetic cannabinoid use. Clin Schizophr Relat Psychoses 2013:1-13: doi:10.3371/CSRP.DUDE.031513.
46. Chandiramani RN. Synthetic legal intoxicating drugs (April 2012). Cleve Clin J Med 2012;79:534.
47. Glue P, Al-Shaqsi S, Hancock D. Hospitalisation associated with use of the synthetic cannabinoid K2. N Z Med J 2013;126:18-23.